Genetically Modified Organisms Are Bad Essay

Genetically Modified Organisms Are Bad Essay
When you think of genetically modified organisms do you think of how they are bad and have no
regulations or do you think of how they help improve our well being. I'm betting it is the second one
because the media has manipulated us into believing these nasty things about GMO's without any
real scientific evidence. I'm sure you heard of GMO's but do you really know what they are.
Genetically modified organisms denotes organism's with DNA has been altered and does not occur
through mating or in nature (WHO). The media portrays GMO's in this negative light because it
makes an interesting story and makes us want to read or watch about it. The media plays on our fear
of the unknown to make us buy in to the lies the tell. Now, you may be against GMO's but do you
realize that they are everywhere. In fact, Dr. Neil deGrasse Tyson, a highly educated astrophysicist,
said that "practically every food you buy in a store for consumption [and is at home] is genetically
modified food" (). ... Show more content on Helpwriting.net ...
If the product does not meet the health and safety standards, regardless of its method of production,
the item is not sold (FDA). The U.S. Food and Drug Administration regulates the food consumed
and medicine prescribed for consumers (FDA). In order for a company to research, produce or
market a drug or food they must first do extensive research and test the product on animals (FDA).
Just like any other drug or food that is produced using non GMO's there are benefits and
consequences. If the drug or food benefits outweigh the risks, the drug is approved for sale
... Get more on HelpWriting.net ...

Work Team Effectiveness & Organization Culture
Running head: WORK TEAM EFFECTIVENESS AND ORGANIZATIONAL CULTURE
Work Team Effectiveness and Organizational Culture
Gene One Benchmarking
March 20, 2007
Gene One Benchmarking
Introduction
Change is not always easy to come by. Sometimes change causes a good thing to go bad, while at
other times it can cause bad things to improve. Businesses have to be ready for change management
at any juncture within their life cycle if they expect to have longevity within the industries that they
operate. However, these changes can only be overcome through positive direction from leaders
within the company and through that organization's infrastructure maintaining similar mindsets
throughout its makeup. Change can carry with it a multiplicity of ... Show more content on
Helpwriting.net ...
Comparison and Contrast
Although these three companies operate in three unrelated industries, mail delivery services,
education, and transportation, these companies reflect that work team effectiveness is topic worthy
of consideration amongst any industry. Furthermore, these three companies convey the same
principles throughout the scope of work team effectiveness. These companies believe that clear
communication across their company's structure creates an environment in which every employee
and client can understand the directions of the company. They maintain the optimal levels of
communication through training their employees as the company or industry standards evolve; then
they convey this knowledge to their clientele. To clarify these concepts of clear communication and
training observe some specific actions of each of these companies as they foster effective team
atmospheres within their organizations.
Leapfrog's leadership teams come together to ponder, network, and conduct open–minded
discussions as they clarify and periodically redefine all stakeholders' perspectives. They believe in
spokesperson representation to signify the sound of one collective voice. UPS covers four categories
to assure their company's leadership is effective. Those categories are 1) enhanced work

Case Roche
Advanced Corporate Finance
Final Case: Roche
Deadline: Wednesday, October 12th, 2011 9:00
Bokhoven, Kim 5876192
Bor, Lisa van den 5933471
Dirven, Mathilde 5883164
Dreteler, Hessel 5921090
Krans, Annemiek 0579327
Rossenaar, Wendy 6043550
Roche, a global pharmaceutical company from Switzerland with Humer as chairman, had owned a
majority stake (56%) in Genentech, a successful pioneer in biotechnology. Genentech had worked
independently for a very long time, and most minority shareholders where employees of Genentech
itself. On July 21, 2008 Roche had publicly offered to buy all of the remaining shares of Genentech
(44%). After this offer of $89 per share had been open for six months, with little progress toward a
deal, Humer ... Show more content on Helpwriting.net ...
Because the expectations are that Genentech's cash flow will remain high, full access to this cash
would be in the benefit of Roche e.g. they could repay the debt used for financing the acquisition.
Risks
Besides the benefits, there are also several risks involved with the takeover. First, the takeover
would cost $44 billion, which partially would have to be financed by debt. The management was not
sure if Roche would be able to raise the required debt funding, given the state of the financial
markets. In the middle of the financial crisis, banks were not very keen in arranging bridge loans to
finance such acquisitions. As a result of this, even if they were able to manage to get a bridge loan,
this would be very expensive.
Secondly, it is very hard to value the benefits to Roche in taking over Genentech. One of the causes
of a misvaluation is that synergies tend to be mispriced. On top of that, Genentech was waiting on
test results of their cancer drug Avastin, which were expected in April 2009. If the acquisition would
take place before this date, Roche bears the risk that the drug is rejected. This would result in a drop
in value of Genentech. The risk that Roche takes by waiting with the acquisition until after the test
results will be published is that if the test results tend to be positive stock price of Genentech would

increase. This increase would make a deal substantially more expensive and thus it would make it
even harder to

BADM 590 Spring 2015 Schedule
University of Illinois, College of Business Administration
BADM 590: Operations Strategy
Schedule of Classes and Assignments for Spring 2015
CLAS #1:
No assigned readings or case discussions. This class is reserved for introductions, familiarization
with the syllabus and course policies, and a review of concepts from the core strategy and process
management classes.
CLASS #2
Case Questions:
1. Which characteristics of McDonald's production system have been most important in building its
record of success and growth?
2. What are the primary new challenges McDonald's faces in the 1990s?
3. How would you adapt the system to accommodate these changes in the U.S.?
4. How can McDonalds lay the basis for future growth?
Readings:
1. ... Show more content on Helpwriting.net ...
How do these figures change if the time required to prepare a patient in the operating room increases
from 30 to 45 minutes?
For all calculations, assume that: (1) Booth only performs unilateral procedures, (2) the first patient
cannot enter the operating room until 7:00 AM, and (3) the entire procedure for the final patient
must be complete by 12:00 PM. Also, note that an operating room is considered non–idle when it is
either occupied by a patient or being cleaned between procedures.
Readings:
1. Kasra Ferdows, Michael A. Lewis, and Jose A.D. Machuca, "Rapid–Fire Rulfillment", Harvard
Business Review, Vol. 82, November 2004 (p. 104–110).
2. Charles Corbett and Luk Van Wassenhove, "Trade–Offs? What Trade–Offs? Competence and
Competitiveness in Manufacturing Strategy", California Management Review, Vol. 35(2), Summer
1993 (p. 107–122)).
CLASS #6:
No formal class or assigned cases. This day is reserved for team meetings and brainstorming about
the projects. Each team should pick a technology to look analyze terms of how it is likely to affect a
particular industry. Alternatively, the team might develop an entrepreneurial idea based on a new

technology.
The following reading provides a good background for thinking about how new technologies might
change organizations and ways in which things get done, so it is helpful to go over before the teams
meet:
CLASS #7:
Case Questions:
1. Compare the JetBlue's operations strategy

From Alchemy to IPO by Cynthia Robbins Roth
The book "from Alchemy to IPO the business of Biotechnology" is a synopsis of the biotech
industry from its inception to late 1900's . Author Cynthia Robbins – Roth writes a first hand
narration from amidst the blooming industry as she was one of the first senior scientist to be
recruited by Genentech. The book gives a complete picture from the roots of biotech , the major
milestones achieved and the process of getting the product out to the market. It also covers the
financers, venture capitalist and the common man's view of the biotech industry from time to time,
during its progression.
My favorite part of the book is the "Roots of the biotechnology". This part of the book talks about
the events that triggered the inception of the industry and the early players who were a part of this
revolution. The main trigger was the deficit of the traditional drug discovery approach where big
pharmaceuticals targeted many small inorganic molecules to enzymes or cell surface receptors in
test tubes and further evaluated initially successful products. This approach did not allow them to
consider side effects and overall efficacy of the drug eventually leading to the failure of most drugs.
The second trigger was the large amount of funding directed to cancer research by the US federal
government and the National Cancer institute. Extensive research proved lymphokines as potent anti
cancer agents but this discovery hit a road block as the scientific community did not know how to

Week 8 Assignment 2 21st Leadership Essay
Week 8 Assignment 2 21st Century Leadership BUS 302 Management Concepts Strayer University
Instructor: Written By March 1, 2015 PROFILE OF MR.ARTHUR D. LEVINSON Mr Levinson is
current CEO of Calico (Google Venture) since September 2013 and chairman of Apple Inc since
2011 to the present. In addition to serving on the board Apple Inc. since 2000 Levinson is currently
on the board of directors of the Broad Institute. He has served previously on the board of directors at
F. Hoffmann–La Roche (2010–2014), NGM Biopharmaceuticals (2009–2014) and Amyris
Biotechnologies (2009–20014). He was the CEO of Greentech from 1995 to 2009 and Director of
Google from 2004 to 2009. He has also authored and coauthored over 80 Scientific ... Show more
content on Helpwriting.net ...
He had a clear vision on how he wanted to move the company forward by flooding the the industry
with his products by a stream of drugs to conquer one's untreatable diseases. He knew there would
be failures, which there were such as AVASTIN and RAPTIVA drugs, but knew he need to keep the
spirits and belief of his followers and employees high and believing in him and his vision. He would
always lead the charge by remaining upfront and central during the action. He showed his attitude
and actions how everyone else should behave. It is Levinson's unswerving commitment as much as
anything else that keeps people going, particularly through the darker times when some may
question whether the vision can ever be achieved. If the people do not believe that they can succeed,
then their efforts would fail. Arthur Levinson led Genentech from a biotech baby to an industry
leader, all the while dealing with serious challenges from competitors. He had a clear vision in his
mind and a vivid picture of where to go, as well as a firm grasp on what success looks like and how
and how to achieve it. When he took over Genentech as CEO the company was under a cloud and
under investigation from the use of Human Growth Hormones without correct approvals for the
methods they were using it, as well as the

Leadership, The And Body Of An Organization
Leadership is an important element in strategy management. Leadership is the link between the soul
and body of an organization (Meinke, 2014). The leadership team drives an organization to success
through effective strategic planning. Strategic planning refers to all efforts that produce fundamental
decisions and actions that are used in shaping and guiding a company to success (Meinke, 2014).
When strategic plans are properly executed, they influence the way employees think and act, which
in turn determines the output and quality of goods and services of an organization, thus the success
of an organization.
Usually, organizations that do not use strategic planning may continuously react to near–term issues
as they arise in business, ... Show more content on Helpwriting.net ...
The top leaders in an organization introduce the need for change in the organization by evaluations
of organizations internal and external environment. These leaders formulate the road map – craft the
strategy – that directs the people toward necessary changes. Then, the mid–level and lower leaders
execute the strategy. On the other hand, the mid–level and lower level leaders tell the people what to
do and how to do. Fundamentally, an organization's leadership levels play various and different roles
that are important for constructing and executing the organization's strategy. This essay will analyze
the importance of leadership in crafting and implementing a strategy. The essay will base its analysis
on interview answers of Paul D'Amico, an employee of Genetech. Mr. D'Amico is a Senior Medical
Science Director in Bio & Oncology, U.S. Medical Affairs.
Crafting Strategy
Before formulating a strategy, leaders have to identify the need for change by careful analyzing the
environment in which an organization exists. In other words, the organizational analysis is the
starting point of the whole process of strategic planning. At this stage, strategy formulation, the
leaders set objectives then analyze both the internal and external environment of the organization.
Porter's five forces model enable managers to assess the forces that make some

The Impact Of Genentech On The New Biotechnology Industry
Genentech was founded in 1976 by Robert Swanson and Herbert Boyer. The company was one of
the first biotechnology companies. Its mission was to develop manufacture and commercialize
biotherapeutics drugs. Genentech main focus was in areas of oncology, immunology and tissue
growth and repair. After few years of company's development, Genentech scientists successfully
produced the first therapeutic proteins which involve human genes. Evaluating with the VRIO
analysis, Genentech is valuable, rare, costly to imitate, and organized to capture value. The main
advantage of the company is that best scientists in the world doing their own research, focusing in
produce the best–in–class medicines with leading–edge scientific knowledge. Genentech has a rare
resource, which provide opportunity for scientists to collaborate with one another. The working
environment is also rare, which provide the scientists with a 275,000 square foot state of the art
facility. Herbert Boyer owns the first major patent in the new biotechnology sector, which no other
companies can duplicate or purchase those patent rights. This factor is costly to imitate because the
company has the patent for a period of time, thus creating a competitive advantage. Genentech is
organized to capture value and sophisticated selection criteria in order to move projects from
discovery phase to commercialization. The projects are mainly based on scientific rationale, critical
medical needs, significant market opportunities,

Drug Pricing: The Healthcare Industry In The United States
The healthcare industry is often monopolized by select medications that are very expensive.
However, the FDA recently approved Ocrevus, a drug that treats severe multiple sclerosis, and is
available at a slightly more reasonable price. An article in the New York Times by Katie Thomas
summarized the pricing, "Genentech, which is owned by the Swiss pharmaceutical giant Roche, said
Tuesday that it would charge a list price of $65,000 a year, which – though expensive – is 25 percent
less than an existing drug, Rebif, that was shown to be clinically inferior to Ocrevus in the two
clinical trials that led to Ocrevus's approval" (March 28th, 2017). I agree with the Thomas'
assessment that we are making improvements in terms of pharmaceutical drug pricing. ... Show
more content on Helpwriting.net ...
In addition, without access to these life changing drugs, some individuals are not able to make
positive contributions to the economy. Looking at the issue of drug pricing from this perspective,
more expensive drug will reduce economic productivity in the United States by eliminating some of
the workforce. Drug pricing has a significant effect on my future career in the healthcare field.
Patients having access to more affordable medications will allow for a healthy population and
increased treatment options. While Ocrevus is significantly cheaper than the current multiple
sclerosis drug options, it is still quite

Innovation as a Motivator Essay
Motivation, an important concept in management theory, can be defined as: "the reasons people do
the things that they do" (Zenisek, 2009). A company that effectively motivates its employees will
often perform better than one that does not. One motivation technique is innovation time: giving
employees the freedom to work on their own projects as a portion of their normal workload. These
projects are entirely self–directed, and rely heavily on the employee's creativity and entrepreneurial
spirit. Innovation time is an advantageous policy for two reasons: it can facilitate the creation of new
revenue streams, and it exemplifies the positive aspects of academically accepted motivation
theories, in particular the job characteristics model ... Show more content on Helpwriting.net ...
Google also adopted this strategy, but altered it to make it fit their corporate culture. At Google, all
engineers spend eighty percent of their time on company assigned projects, and twenty percent of
their time on personal or group projects (Google, 2009). Google's implementation of the technique
is unique because it adopts additional motivational theories in the administration of the twenty
percent rule. Google ensures that employees remain motivated in regards to their projects through
constant feedback and review. Each employee submits a weekly description of the progress made on
their personal project and attends regular peer review meetings (Girard, 2009). The feedback gained
from these meetings helps the employee to brainstorm solutions to problems and remain focused on
their project goals. As well, peer review sessions allow engineers see what their colleagues are
working on, and provides them with the opportunity to join other projects. Although innovation time
could apply to many types of companies, it has been proven most effective in organizations with a
technical research focus. One primary reason for employers to implement innovation time as a
motivator is to expand new product lines and revenue streams. One example of this is 3M's popular
product created by Arthur Fry, the Post–It Note. Fry was frustrated that the bookmarks

Strategic Requirements Of Modern Healthcare Essay
With the globalizing of the healthcare market, as a consequence many healthcare organizations face
many challenges. The management is not as simple as it once used to be, as they not only need to
focus on providing quality care, but they also need to focus on suffusing many patient–centered
demands, organizational needs, and stakeholder expectations. Therefore, the healthcare
organizations are implementing many strategic tools and methods in order to fulfill the strategic
requirements of modern healthcare. One such great strategic tool used is SWOT analysis, which
evaluates the organization's internal and external strengths, weaknesses, opportunities, and threats.
To elaborate more on the effectiveness of the SWOT analysis, it was applied to my current
organization called Genentech. Background Information on Genentech Genentech is a
biotechnology organization that discovers, develops, manufactures, and markets bio therapeutics for
several unmet medical needs such as in the areas of oncology, immunology, growth, asthma
metabolism, mental disorders, dermatology, nephrology, neurology, urology, and rheumatology
("Genentech," n.d. a). In 2009, Genentech merged with an international pharmaceutical company
called Roche (Research and Marketing, 2012). Its headquarters in the Unites States is located in
South San Francisco ("Genentech," n.d. a). I work for the department called the Genentech Access
to Care Foundation (GATCF), the primary purpose of this department is to provide

Essay on Genentech
Case Study: Genentech
Discussion Questions
1. Would you characterize Genentech's employees as experiencing distress or eustress?
Distress is the type of stress that has negative implications, whereas eustress has a positive form of
stress, usually related to desirable events in someone's life. Therefore, I would characterize the
Genentech's employees as experiencing eustress. For example, all these programs that Genentech
offers to its employees make life less stressful. The employees, who work for Genentech, enjoy
working and they are proud of the cancer–fighting drugs their company produce, and also the
egalitarian policies.
2. How can the Yerkes–Dodson law be related to the impact of Genentech's programs ... Show more
The company maintains a corporate culture that fosters creativity and innovation. Therefore, the
company allows its researches to publish their findings in academic journals. Genentech also
promotes emotional health among its employees by creating a connection culture, for example,
bringing cancer patients into the company's facilities. Another way that the company promotes the
well–being of its employees is the availability of its tuition–assistance program to cover educational
expenses of its employees. And another important initiative and well–being for Genentech is helping
its employees maintain balance between their work lives and personal lives. As a result, Genentech's
employees claim that they love what they do because they know their job has a meaning.
4. What might be accomplished by Genentech's programs with respect to enabling employees to
better deal with workplace stress or its consequences?
All these programs deal with employee stress and or well–being at workplace, and are aimed at
making life less stressful. Consequently, Genentech employees consistently refer to the opportunity
to make a difference in the lives of patients as the primary reason they work for Genentech.
Genentech's development products continue to grow, with multiple promising projects in the
following therapeutic focus area: oncology, immunology, metabolism, neuroscience and infectious
diseases. As a result, they

Genetic Engineering Of Food Products Essay
Genetic engineering of food produce is considered a miracle technology. Many speculate that this
discovery has the possibility to end world hunger. By mass producing and marketing produce, the
associated costs will decrease. With lower production costs for crops, healthy options will not only
be more accessible, but more affordable for customers as well. Some even contend that the overall
health of the general population will improve. How does this affect the healthcare industry? If we
can genetically modify food, why not humans? By accepting and utilizing engineered produce as a
viable food source, many express it would eliminate the need for trade, because each country would
be capable of producing its own food. Which corporation(s) would corner the market? If genetically
engineered goods permeate the market, a trading would become obsolete. An intense plunge in the
value of produce would agitate the stock market. The eradication of trading produce would cripple
most, if not all, economies (Gandel, 2010). Though genetic engineering of food has drawbacks, the
benefits arguably may manage to outweigh them. The total dissolution of world hunger is an
impressive feat. But, do the perceived benefits of genetic engineering make the hassle of starting a
business worthwhile? Have the potential threats to democracy along with the socioeconomic
implications associated with the utilization of new and emerging human engineering technologies
thoroughly been considered?

Roches Acquisition of Genentech
February 11, 2011 Dear Valued Scotiabank Customer, In an effort to keep our customers informed,
we would like to update you on the Payments Systems Reform process being implemented by the
Bank of Jamaica (BOJ). e BOJ implemented a Real Time Gross Settlement (RTGS) system in
February 2009. e RTGS is an on–line funds transfer system where the transfer of money is effected
from one bank to another in "real time". e BOJ has indicated that effective March 31, 2011, financial
transactions with a large value (i.e. $5,000,000 and above) are to be cleared via the RTGS system
instead of the "regular clearing" system (Automated Clearing House/ACH), where all cheques are
now cleared. Consequently, the BOJ will impose a penalty of $5,000 on any ... Show more content
on Helpwriting.net ...
Another option, providing you have signed our fax and email indemnity form, would be to email or
fax your instructions with the necessary details to your branch. Q – Will I still be able to write
cheques valued at J$5,000,000 or more? You can still write cheques valued at JMD $5million or
above, however if these items are presented at another Bank, it will incur the deferred penalty fee of
$5,000 per item as imposed by the BOJ, and this fee (plus GCT) will be subsequently charged to
your account. Please be reminded that should the BOJ determine that the volume of large value
transactions has decreased by 50% then your account will be credited the penalty fee at that time. Q
– When will I know whether the volume of large value transactions has met the BOJ's target of 50%
and thus know whether my account will be reimbursed? It is expected that BOJ will advise
Scotiabank about this at the beginning of 2012. As soon as we are notified we will pass this
information to our customers and reimburse your account at this time (assuming the 50% or greater
reduction in volume was achieved). Q – I don't have a chequing account but from time to time I
would request a Manager's Cheque. Will this fee also affect me? Because this fee applies to all
cheques, including Managers Cheques and corporate cheques issued for JMD$5 million or more,
Scotiabank will no longer be issuing Manager's Cheques valued at JMD$5 million or over. However
you will be able to electronically

Mitosis Research Paper
Mitosis is a type of cell division that results in two daughter cells that are identical and each having
the same number and kind of chromosomes as the parent nucleus, which is typical of ordinary tissue
growth. Each daughter cell also carries identical DNA of the parent cell. Errors in mitosis can result
when there is an incorrect DNA copy called aneuploidy. The effect of errors on the health of the cell
ranges from benign to cancerous, depending on the amount and type of errors. All cancer types are
traced back to harmful mutations multiplied by mitosis.
There are four stages of mitosis: prophase, metaphase, anaphase, and telophase. In prophase the
chromatin shrinks into separate chromosomes, and the nuclear envelope breaks down and forms ...
Show more content on Helpwriting.net ...
Scientists from George Washington University medical center have found a missing link in mitosis
that brings hope for cancer researchers. They have found a protein known as Arpc 1b that is an
activator for an enzyme called Aurora A that is important in early stages of cellular reproduction.
Cells divide and separate poles to create new cells. If all goes well two new cells are produced, but
in some cases the protein is over used, and abnormal cells are produced which lead to cancer.
Pharmaceutical industries are targeting Aurora A and trying to prevent it. This is the next step to
help scientists find a way to stop the activity of Arpc in cancer cells. As an example, Genentech is a
leading biotechnology company that discovers, develops, manufactures and commercializes
medicines to treat patients with serious or life–threatening medical conditions. They are among the
worlds leading biotech companies, with multiple products on the market and a promising
development pipeline. At Genentech, James Sabry, M.D., Ph.D. who is the Vice President, said, "If
we understand basic science, our drugs make it to market. If we don't, the company dies." Roche,
Genentech's parent company, spends more on research and development than any country in the
world ($9.5 billion annually). Understanding cell development and cell division help the

Using the Mid Text Function/Moving and Copying...
Questions for the Roche case Case write–ups due on Wednesday, March 30, at 8:10 pm 1. Why is
Roche seeking to acquire the 44% of Genentech it does not own? From Roche's point of view, what
are the advantages of owning 100% of Genentech? What are the risks? (1 pt) Roche already had
56% of shares of Genentech and now it seeks to acquire rest of the 44% shares so as to get the
benefits of synergies. The pharmaceutical companies have been unable to introduce new products
lately, and their only way to remain profitable is by mergers and acquisitions. Roche also used this
method. Acquisition will help the firm compete in the market and thus will help it grow. Advantages
of owning 100% of Genentech's shares: * 1 The merger will ... Show more content on
Helpwriting.net ...
| | | | | | Enterprise value | 72676 | | | | Commercial paper | –500 | | | | Long term debt | –2329 | | | | Cash
and securitization | 9000 | | | | Equity value | 78847 | | | | Shares outstanding | 1052 | | | | Value per
share | 74.9 | | | | Following table shows the possible values of value per share as affected by different
annual and long term growth rates. | | | | | | | Annual/long term growth rates | 1% | 1.55 | 2% | 2.50% |
3% | 5% | 61 | 63 | 66 | 69 | 72 | 6% | 65 | 67 | 70 | 73 | 77 | 7% | 69 | 72 | 75 | 78 | 82 | 8% | 73 | 76 | 79
| 83 | 87 | | | | | | | Range of values per share is from $67 to $83 per share. This is in range of
Greenhill's own calculations. | WACC also has impact on the above range of values. Changing the
WACC from 9% to even 8% or 10%, will change the range to $65 to $87. Fundamentals behind
WACC: Market risk premium | 7.10% | Beta (as of July 2008) | 0.26 | Beta of equity | 0.3066 |
Treasury yield (as of July 2008, 10 years) | 4.01% | Cost of capital | 6.18% | Commercial debt | 500 |
2.08% | | Long term debt (AAA) | 2329 | 5.67% | | Total debt |

Dealing with Stress...The Genentech Way Essay
Every large organization has its own way to deal with "Stress". This case explains the Genentech
way of dealing stress. Genentech is the first biotech company and was founded in 1976 by Dr.
Herbert W. Boyer, a biochemist, and Robert A. Swanson, a venture capitalist. Like any other major
large corporation Genentech aspired to be the leading biotechnology company. It has been
recognized to be a very people friendly company for its Human resources policies and its human
therapeutics.
In 2007, Genentech CEO Arthur Levinson, wanted to make his company a great place to work and
recognized by the industry and magazines. This desire made Genentech adapt some culture that
helped the employees to reduce stress and made the company one of the top ... Show more content
on Helpwriting.net ...
When you are a company that is highly recognized for being one of the top 100 places to work for in
the United States, for the eleventh year in a row, according to "Fortune magazine," and recognized
in other noted magazines giving the same attention to Genentech and its employees, I would
strongly believe that Genentech's employees would be viewed as experiencing eustress. There have
been several employees' who have expressed their satisfaction on "YouTube," with being employed
with Genentech. Jennifer Cook, Senior Vice President Immunology and Ophthalmology, states "The
opportunities are not too pre–specified and not predefine for you, it about taking advantage of the
opportunities and the talent that people have and letting them really contribute everything they
have."
Joan Greve, Scientist Biomedical Imaging Group expresses a positive reason to come to work at
Genentech when she views work as fun by interacting with people every day, which provides high
energy, motivation, and enthusiasm about the end–goal.(ht) (Genentech)
In my opinion the employees at Genentech are in eustress. I work for Amgen, which is also one of
the top of the list companies to work for. In my 7 year experience in the company I have
experienced both eustress and distress.
2. How can the Yerkes–Dodson law be related to the impact of Genentech's programs that are aimed
at enhancing employee well–being?
Yerkes–Dodson law can be related to the impact of Genentech's

The Dynamic Evolution of the Biotech Industry
The evolution of the basic science supporting the growth of biotechnology is fascinating, but for me,
well understood, from the fundamentals of recombinant DNA technology and taking advantage of
basic model organisms to study and manipulate genetic information, to utilizing the biochemical
properties of DNA, RNA, polypeptides, and other macromolecules to elucidate the seemingly
endless body of biological knowledge – different methods of sequencing including high throughput
methods utilizing arrays and fluorophores, as well as supporting technologies such as polymerase
chain reaction (PCR) to increase the amount of starting material from even the tiniest number of
isolated molecules. What is lesser known to me, as well as a tragic fact of life, is the business side of
biotech. The dynamic evolution of the biotech industry overtime, however, is quite fascinating and a
delight to learn about, from the fertile grounds for biotech ventures and startups of the early market
to the trending 'urge to merge.'
Genentech is a ripe exemplar of the highly adaptable and productive initial pool of 1st generation
biotech companies. Genentech not only developed the novel recombinant DNA technology but also
maneuvered through the established world of drug development with expertise, leveraging its new
technology into products commanding high value while founding strategic corporate partnerships.
The evolution of this market saw the huge successes of IPO's in the late 1980's to mid 90's, and

Project Control Systems Integration
Reprinted from PHARMACEUTICAL ENGINEERING®
The Official Magazine of ISPE
September/October 2011, Vol. 31 No. 5 www.ISPE.org ©Copyright ISPE 2011
The article presents the implementation of a suite of software packages that together provide a total
Enterprise
project management system.
The Science of Project Management:
Project Controls Systems Integration by Frederick Cramer, Susanne Keller, Christopher Law,
Thomas Shih, and Britton Wolf
G
The concepts in this article were applied to the
ECP–1 Facility,
Overall Winner of the 2010
Facility of the
Year Awards.
For further information on this project, see
"Case Study:
Genentech's
ECP–1 Bacterial
Manufacturing
Facility, Overall
Winner, 2010
Facility ... Show more content on Helpwriting.net ...
The "Project Controls" and
"Benchmarking" sections of the map were to be considered as a suite of integrated, off–the–shelf
tools that would communicate and pass data. A set of requirements for these tools was identified
September/October 2011 PHARMACEUTICAL ENGINEERING
1
Project Controls Systems Integration

Figure 1. Functional tools concept map.
and the project was initiated. Concurrently, a cross functional team developed a set of Good
Engineering Practices (GEPs) that detailed all of the business processes underlying the
Project Services functions of estimating, scheduling, cost, change, and risk management. The GEPs
incorporated much of the native knowledge of the
Project Management group along with industry best practices. After intensive vetting by an
extensive review process, these practices served as the basis for engagement of PCSI. After
considering these requirements and implementing a strict bid and award phase, the solutions chosen
were Skire Unifier for cost and change management, Primavera and Microsoft
Project for project and portfolio planning, Timberline for estimating, and
Advisor for benchmarking – Figure 2.
The first was an increased competency in development of high level cost ideas/ options with a +/–
50% accuracy for long range planning. The second required a flexible way to develop detailed
internal
Estimating and
Benchmarking
During Genentech's rapid

The Effect of Biotechnology on World Economy and Society
Cynthia Robbins–Roth's book "From Alchemy to IPO: The Business of Biotechnology" is a must
read for those who are passionate towards the field of biotechnology. It offers a complete insight on
the exciting world of biotechnology, right from its initial stages in the 1970's and 1980's. For many
centuries now, biotechnology has been in practice such as to bake bread, brew alcoholic beverages,
and breed food crops or domestic animals. But recent developments in molecular biology and
genetics, have given biotechnology new meaning, new prominence and new potential. It has
captured the attention of the public. Modern biotechnology can have a dramatic effect on the world
economy and society and this is the underlying statement throughout the book.
In the first section, the author starts by explaining the rise of three major biotechnology companies,
Genentech, Amgen and Genzyme and their competition with the big pharmaceutical companies.
These companies had and have the best working researchers when compared to the pharmaceutical
companies. As a former employee of Genentech, the author also gives accounts of inside stories. For
example, the interactions of employees with Bob Swanson (founder of Genentech). She then moves
on to the research aspects of biotechnology and gives an account of the various genetic engineering
tools and techniques used such as Biochips and Microarrays .Other topics covered include tissue
regeneration ,treating diseases using antisense drugs, somatic

Week 6 Case Study
Week 6 Case Study: A Perky Way to Productivity
1. It is important for employees to receive benefits that meet their needs. When employee needs are
met they are happy, turnover rates may decrease, and employees complain less. Employees are more
likely to do a better job because they feel appreciated and needed at work which boosts the
workplace morale. HRM goals will be met in that employees will be doing a great job, which allows
them maintain the effectiveness of the company. HRM's goal is to keep the company running to
continue to produce a positive profit and this can be done if employees are taken care of properly.
Most new hires are attracted to the high basic salary or hourly wage. Therefore, employee benefits
need to be ... Show more content on Helpwriting.net ...
This particular incentive would hit a homerun in my book. Flexible work scheduling is another great
perk because it would allow employees to schedule activities from their personal life into a time
frame that works for them without creating an issue with attendance at work. The six week paid
sabbaticals is yet another great benefit that could keep employees from feeling overwhelmed with
work and sometimes home activities that could decrease employee morale.
A full–time life coach is another great asset to the company. Not only are you getting the
encouragement that you need to help you maintain a healthy work life style, but it will also help you
maintain a healthy home life style. If you are happy and healthy at work and home, this will increase
your productivity at work and home. Having a life coach can help assist you in maintaining a
desired life style.
Overall, all of the incentive benefits can give employees the extra boost they need to make it
through the day at work and home. These benefits have the potential to increase the value of every
employee in the company and lessen the turnover rate.
Reference
DeCenzo (2010). Fundamentals of Human Resource Management [10] (VitalSource Bookshelf),
Retrieved from

South San Francisco City Council Case Study
¬Structure of Government:
City Council; Consists of five members, elected to 4–years term The governing core of South San
Francisco is the city council, which creates municipal laws and the overall policy, decides how to
expend treasury, assigns members to all consultative local businesses and represents the city
officially. The city council`s members are Richard A. Garbarino as a mayor, Mark N. Addiego as a
vice mayor, Pradeep Gupta, Karyl Matsumoto and Liza Normandy.
City Clerk; elected to 4–years term The city clerk is the curator of the city`s documents. The city
clerk`s office is the channel between the local residents and the local government It is also the city
clerk`s responsibility to provide the general public with any required information. The current city
clerk of South San Francisco is Krista Martinelli.
City Treasurer; elected for a 4–year term The city treasurer is in charge of investing the city`s
treasury to obtain the most profitable returns, coordinating any financial transactions and preparing
property tax valuations. The current city treasurer of South San Francisco is Frank Risso.
City Manager The city manager is the head managerial officer of the city and is responsible for
providing overall management and directions for the city organization. The city manager is
delegated by the city ... Show more content on Helpwriting.net ...
The Genentech Goes to Town program provides employees with $25 daily for two weeks every day
to spend at local businesses. The program has benefited over 250 businesses at South San Francisco
community. Moreover, in a partnership with Genentech and BayBio, South San Francisco hosted the
Biotechnology and Workforce Development Summit to encourage students to pursue their careers in
Biotechnology. The summit also aimed to encourage local industries and academic institutions to
cooperate to prepare students for bright careers in the biotech

Rituximab Research Paper
Rituximab, better known by its trade name Rituxan®, is a monoclonal antibody medication
administered intravenously. Genentech, Inc and IDEC Pharmaceuticals manufacture Rituximab. 1,3
It is a drug used to treat several diseases including: Rheumatoid Arthritis (RA), along with other
prescribed medicines; Non–Hodgkin's Lymphoma (NHL), either alone or with other chemotherapy
medicines; Chronic Lymphocytic Leukemia (CLL), along with other chemotherapy medicines
fludarabine and cyclophosphamide; Granulomatosis with Polyangiitis (GPA); and Microscopic
Polyangiitis (MPA), along with glucocorticoids. 1,2 Cost of treatment varies on the disease.
Rituximab costs are about $ per mg/l .
Rituximab is a genetically engineered chimeric human–murine antibody. 3,4 More specifically,
Rituximab is composed of the ... Show more content on Helpwriting.net ...
4 This antigen is present on more than 90 percent of B–cell NHL. However, it is not found on
hematopoietic stem cells, normal plasma cells, pro B–cells, or other normal tissues. CD20 has other
key roles such as in the activation process for cell cycle initiation and differentiation and it is
suspected to function as a calcium ion channel as well. In RA, b–cells play an important role in the
pathogenesis and associated chronic synovitis. In RA, b–cells act on multiple sites to induce an
autoimmune inflammatory response including the production of rheumatoid factor, other
autoantibodies, antigen presentation, t–cell activation, and pro–inflammatory cytokine production.
The fab domain binds to the CD20 antigen on b lymphocytes and Fc domain recruits immune
effector function to mediate B–cell lysis in vitro. Potential mechanisms of cell lysis involve
complement–dependent cytotoxicity (CDC) and antibody–dependent cell mediated cytotoxicity
(ADCC). In addition, the antibody has been shown to induce apoptosis primarily in the DHL–4
human B–cell lymphoma

In 2014 They Had Issued Over 486,000 Shares Where Each
In 2014 they had issued over 486,000 shares where each one cost around .28 cents. "When they
originally began, most of their funds came from healthcare investors and funds" (SEC, 4). In the
SEC it states that they have been able to have raise over 108 million in preferred stocks, 99.9 million
in cash, cash equivalents and marketable securities and have a deficit of 25.5 million. On the
balance sheet for 2015 the assets of the company are $101,603 in 2014, which is an increase of
2014's numbers of $12,529. On the S1 as of 2015 Corvus has had a total of 15,767,250 shares and
common stock equivalents which has increased from the 4,196,494 from 2014. Since Corvus
Pharmaceuticals recently began and offered a lot of stock options it has ... Show more content on
Helpwriting.net ...
Market Sector The market sector Corvus Pharmaceuticals is currently in is in the healthcare sector
of the economy. The price is of their stock is $9.99 and it has kept going up They are developing
drugs that are involved with cancer which means the competition is great. After looking at Morning
Star it looks like Amgen Inc., Celgene Corp, and Gilead Sciences Inc. are some of the competitors in
their field. All of them have had positive cash flows, and they're stock prices are significantly higher
than Corvus's stock price. Corvus currently has a negative cash flow, but is still in the stages of
development so over time that will begin to change if the drugs they produce successfully work
during the trail runs.
Strategy
On the S1 Corvus Pharmaceuticals main strategy is to "become a leader in the field of immuno–
oncology treatments for multiple cancer indications." (S1, 5). In order to achieve their goal CRVS
has 5 elements to achieve it and they are: due to the employee's skills and knowledge in
immunology and oncology it allows them to research and develop new products. Corvus has also
used data from previous trials to help them on the CPI–444 for oncology. The use of products that
can be used for treatments. "Identify biomarkers to select patients and monitor treatment with our
product candidates" (S1, 5) and partner with

Pancreas Center Case Study
New to The Pancreas Center team is Zoe Anderson, a Clinical Research Navigator in the Medical
Oncology team!
Zoe graduated from Johns Hopkins University with the intention of entering the health care field.
Her role within the center is to act as a main point of contact for patients interested in clinical trials.
She is an integral part of the research team. She gathers new patient information, studies and
disseminates information on the active trials and works with her team members to enroll patients
into trials. She works closely with patients by assisting them with the navigation of complex clinical
trials and also familiarizing patients with the medical approaches and terminologies used.
Zoe shares her thoughts on the below new and exciting study with Columbia's own dr. Gulam Manji
as the Principal Investigator. ... Show more content on Helpwriting.net ...
Roche–Genetech is a biotechnology research company that created MORPHEUS which is a Phase
1b/2 new pancreatic cancer immunotherapy development

Genentech Paper
GENENTECH: What links the Motivation of their Employees and their Economics? Many
companies now recognize the value of investing in their human capital (NYtimes.com, 2006, para
1). A biotechnology company, Genentech, has proven that there is a direct link between motivated,
happy employees and economic success. By providing several special programs and positive
reinforcers to assist their employees and making life a little easier, the employees show pride and are
dedicated and motivated to doing their jobs and performing above average. Because of the
employees increased efforts Genentech has increased their profits, created world class medicines,
and have been recognized numerous achievement awards. Genentech is recognized as leaders in the
biotechnology industry (Genentech.com, 2015). The company was founded in April of 1976 by
Herb Boyer, a biochemist, and Bob Swanson, a ventured capitalist. Genentech is now members of a
Swiss pharmaceutical powerhouse called the Roche group. The company is known for its progress,
profitability, and dedication to serving the people. ... Show more content on Helpwriting.net ...
There are different ways to motivate people one way is intrinsically, or internal. For example that
deep pride the employees feel about their job because they are doing something that will help
another person and potentially save lives. "I feel grateful and proud that whether I'm working in the
lab or at my desk, my work will in some way help someone with a significant medical condition,"
said one of the employees at

Genentech Case Study
1. Work diversity initiatives does the company have in place? Genentech is a biotechnology industry
with many diversity initiatives in place. This company has groups and goals set up just for
diversities. The company has strategies in place based on research to bring more women in the
industry and retain them. "The strategy is based on the E.D.G.E. (Empowerment, Diversity, Growth,
Excellence) in Leadership study conducted by the Healthcare Businesswomen's Association (HBA)
and Booz Allen Hamilton." (Genentech. 2016). This company places a lot of dedication to the
employment and growth in the industry for women. Also, Genentech has a group for employees set
up called "DNA (Diversity Network Associations)." (Genentech. 2016). This group is made up of
partner organizations based upon different diversities. They use these partnerships formed to bring
awareness to the biotech industry and possibly obtain good leaders by the attracting them to
Genentech. "DNA groups serve as a vital connection between employees, leadership, local
businesses and community organizations." (Genentech. 2016). ... Show more content on
Helpwriting.net ...
They have managers that explore the skills obtained in the military for hiring those that can bring
something to the industry and further it's initiatives. They also have an equal opportunity
employment program set up. This program is in place to base their industry on the value of the
individual's performance and qualifications, not on race, gender, or other diversities. This company
seems to have many programs and strategies in place for diversity. "We've made it our mission to
improve diversity of all kinds and at all levels." (Genentech.

Pyloric Disease Research Paper
Affecting over three million Americans, GERD is a serious problem in the United States. Gastro
esophageal reflux disease (GERD) is a chronic condition that affects both children and adults that
can lead to other more serious diseases. Thankfully, the American Medical Association has now
recognized Hemophilia as a serious concern in efforts to increase its research funding. However,
Celiac Disease has also received the endorsement of the American Medical Association this year. As
Genentech is the nation's leading research corporation, both diseases will likely compete for your
support. I highly advocate that Genentech allocate all funds and research resources available to
GERD, as it is a disease that can make everyday activities painful. GERD is a condition caused by
stomach acid or stomach content coming up from the stomach into the esophagus. This backwash
causes irritation in the esophagus, as the stomach acid damages the esophageal lining. Most cases of
GERD occur in infants and adults. For infants, the most common cause of GERD is due to pyloric
stenosis, a condition that affects the gastrointestinal tract as it narrows the pylorus. This causes food
to flow backward as it cannot make its way to the stomach, thus causing the baby to vomit. In
adults, the most common cause of ... Show more content on Helpwriting.net ...
This damage can make it hard for individuals to absorb nutrients, which can lead to general health
problems. Celiac disease can affect individuals of all ages as the disease is hereditary, with
individuals that have a first–degree relative with Celia disease have a 1in 10 risk of having the
disease. Celiac disease can lead to constant diarrhea and weight loss as the body is not able to digest
food properly. This can lead to constant feeling of fatigue and body pain due to the lack of necessary
nutrients such as calcium and

Trastuzumab ( Herceptin ) -research And Development
Trastuzumab (Herceptin)–Research and Development
Introduction
Cancer is the uncontrollable division and growth of abnormal cells resulting in formation of an
aggressive tumour. In some forms of Breast cancer, the cells proliferate uncontrollably due to over–
expression of the protein HER2 (Human Epidermal Growth Factor Receptor 2); a receptor
embedded within the membrane of cells, allowing for the transfer of signals outside to inside the
cell. Trastuzumab is a monoclonal antibody administered through intravenous infusion, to be taken
on its own or in combination with one or more chemotherapy regimens. It reduces risk of the cancer
reoccurring or spreading by inhibiting the effects of HER2, and enhancing the body's immune
system.
Breast cancer through history
Breast cancer has been acknowledged for centuries, with records dating as far back as the ancient
Egyptians, over 3500 years ago (1). However diagnosis, research and progress throughout history
have been slow due to it being a matter of taboo and humiliation. In 1957 the idea of surgically
removing the tumours was suggested by Henri Le Dran, introducing mastectomy to the 20th
century; the first scientific step in acting against cancer. Radical mastectomy lengthened survival,
however was often declined due to the disfigurement left behind. To overcome this, Bernard Fisher
published results from 'breast conserving' surgery accompanied by radiation or chemotherapy, which
were 'just as effective' as a radical mastectomy (1).

Orphan Drug Report
Orphan Drug Report
An orphan drug is a drug designed to treat a rare disease or condition. For a drug to qualify for
orphan status both the drug and disease or condition must meet certain criteria specified in the
Orphan Drug Act (ODA). This designation would qualify the sponsor of the drug for developmental
incentives which includes waiving of regulator fees, faster or simpler clinical trial and approval
process, tax credit or grants to offset research and development, and a period of marketing
exclusivity which means no competition for many years. it does not mean that the FDA is less strict
when it comes to safety and effectiveness. All of this is specified within the FDA's implementing
regulations at 21 CFR Part 316. It's ... Show more content on Helpwriting.net ...
There are a great many side effects the most common include fear, increased cough, lack or loss of
strength, night sweats and throat irritations The primary means of dosage is through intravenous
injection and the strength depends on the condition it is being used for. These conditions include
non–Hodgkin's Lymphoma, Rheumatoid Arthritis, Chronic Lymphocytic Leukemia, Wegener's
Granulomatosus, Microscopic, Polyangiitis. The life threatening side effects of using Rituxan
include abnormal heart rhythm and liver damage.
Another example is Gleevec from Novartis Oncology this drug went on to have non–orphan
indications; it had sales of $2.4 billion in 2010. The brand name of the drug is Gleevec and the
generic name is Imatinib. This drug interferes with the growth of some cancer cells. Gleevec is used
to treat certain types of leukemia (blood cancer), bone marrow disorders, and skin cancer, or certain
tumors of the stomach and digestive system. The most common side effects include Acid or sour
stomach, belching, difficulty having a bowel movement (stool), difficulty with moving,
discouragement,excess air or gas in the stomach or intestines, fear or nervousness, feeling sad or
empty, feeling unusually cold, full or bloated feeling, increased bowel movements, irritability, lack
or loss of strength, loose stools, loss of interest or pleasure, muscle stiffness, night sweats, passing
gas,

Genentech Biotechnology
The birthplace of Biotechnology is located in South San Francisco, CA, where Genentech was
started in 1976. Biochemist Dr. Herbert Boyer and Robert A. Swanson were the founders of
Genentech, and from 1995–2009 Arthur Levinson had become the CEO of Genentech; presently it is
Ian T. Clark. Genentech is the leading biotechnology company that uses human genetic information
to discover, develop, manufacture and commercialize medicines to treat people with serious life–
threatening medical conditions (2014).
Biotechnology is the technology based on the science of cellular and biomolecular processes. The
processes develop technologies and products that help improve the lives of people and even affect
the health of our environment. Biotechnology uses cellular and biomolecular processes by using
molecular mechanisms by which genetic and metabolic processes occur in plant, animal, and
microbial organisms. By using this technology, it provides breakthrough products and technologies
to combat debilitating and rare diseases, reduce our environment footprint, feeding the hungry, uses
less energy and cleaner energy, and has safer and cleaner and more efficient industrial
manufacturing processes. The many factors they are driven to prevent in our environment overall
affects our human health. Genentech provides products in the areas of immunology, oncology, and
disorders of tissue growth and repair. A familiar life–threatening disease is cancer. Whether it is
melanoma, ovarian cancer, or

Leading Biotechnology Company: Genentech Essay
Located in South San Francisco, CA, Genentech was started in 1976 by a biochemist Dr. Herbert
Boyer and Robert A. Swanson. From 1995–2009 Arthur Levinson had become the CEO of
Genentech; presently it is Ian T. Clark. Genentech is a leading biotechnology company, using human
genetic information to discover, develop, manufacture and commercialize medicines to treat people
with serious or life–threatening medical conditions (2014). Biotechnology is the technology based
on the science of cellular and biomolecular processes to develop technologies and products that help
improve peoples' lives and the health of our environment. How biotechnology uses cellular and
biomolecular processes are by using molecular mechanisms by which genetic and ... Show more
According to Nelson and Quick the Yerkes–Dodson law is characterized by the idea that optimum
stress leads to increased work performance (p.112). The law explains that a person will perform at
peak performance level when healthy amounts of stress are introduced into their work environment.
Stress is a mismanagement of energy in the response, or unique vulnerabilities in a person (Nelson
and Quick, p.112). However, at points past healthy stress levels one should expect a diminishing
return, as the individual are overstimulated and become emotionally exhausted. For instance,
professional athletes are often expected to perform at this peak level of stress, thus producing high
amounts of energy and performing at the expected levels. Individuals who do not experience stress
stimulation often perform under expected levels and are often bored and not satisfied with work,
which could result to distress. The positive stress ideology has been adopted by Genentech and
makes them a staple in the work force for employee satisfaction.
Genentech has created the perfect match between Yerkes–Dobson law and employee feedback to
become a Forbes Top 100 Company. Genentech encourages employee teamwork while also focusing
on the importance of individual creativity and initiative. Employees are expected to perform at peak
levels and the company will provide them with positive stimulation. Genentech has created

Genentech
Business models are most often designed to facilitate profit for a company. There is a twofold
challenge associated with competing in a pseudo–pharmaceutical industry. Genentech, a company
that originally aspired to achieve blockbuster results similar to large pharmaceutical companies,
encountered both challenges.
Genentech was founded in 1976, by Robert Swanson and Herbert Boyer. Genentech's goal was to
take advantage of technology that would create a new identity for the drug producing industry.
Genentech was able to successfully transfer a gene from one species into another. Genentech
established a basis for operation through technology known as recombinant DNA. The recombinant
process allows scientist to take DNA from multiple sources ... Show more content on
Helpwriting.net ...
Genentech was able to achieve stellar results through biotechnology research. Genentech's efforts
led to the world's first biotech, founded more than a quarter–century ago. Genentech was the first
biotech to go public and the first to bring a genetically engineered drug to market.
Genentech's second challenge was manifested in deciding which business model to use. Genentech
had to assess if pioneer technology that creates artificial DNA could flourish in a generating money–
making product. During the genesis of Genentech, a conscious decision was made to assimilate the
business model of large pharmaceutical companies. The pharmaceutical industry was driven by the
creation of blockbuster producing drugs. This decision to adopt this business model was made
despite the industry's giants facing decline in sales from expiring patents and lack of new innovative
drugs to replace them.
Genentech struggled to blaze a trail out of the drug–industry swamp. By the late 1980's, the
company began to show promising results. Genentech had altered its business model toward
medicines that enhanced rapid advancements in diagnostics, genomics and biotechnology for
personalized medicine. Genentech focused on five therapeutic areas: oncology immunology,
neuroscience, metabolism, and infectious diseases (Chatman,

Dsa223
|FIN |Genentech |5/02/2011 | |
|Discussion Questions |Key Players / People |
|Why is Roche seeking to acquire the 44% of Genentech it does not own? From Roche's point of
view, what are the advantages of owning 100% of Genentech? What are the |Arthur Levinson–
Gen''s Chairman and CEO |
|risks? Can Roche finance this deal? ... Show more content on Helpwriting.net ...
| |
|Currently, although Roche is the majority shareholder, it does not have full control of the decision
making process which is very prolonged due to the minority | |
|shareholders | |
| | |
|Risks of acquiring Gen: | |
|Vital IP walking out of the door with some of Gen's scientists, who would leave the company
because of fear that Gen would lose its independence and entrepreneurial | |
|spirit

Promoting Brand Loyalty at Abercrombie & Fitch
Promoting Brand Loyalty at Abercrombie & Fitch ch.6
Abercrombie and Fitch is an American retailer that focuses on casual wear for consumers aged 18 to
22. It has over 300 locations in the United States, and is expanding internationally. The company
also operates three offshoot brands: Abercrombie, Hollister Co., and Gilly Hicks. The company
operated a post–collegiate brand, Ruehl No.925, that closed in early 2010.
The company operates 1,073 stores across all four brands. The A&F brand has 316 locations in
the United States, four in Canada, one in London, one in Milan, one in Tokyo, one in Copenhagen,
one in Madrid, one in Paris, one in Brussels, one in Dublin, and one in Hong Kong. A&F stores
range from 6,000 to ... Show more content on Helpwriting.net ...
Net income from continuing operations was $79.0 million and net income per diluted share from
continuing operations was $0.89 in Fiscal 2009, compared to net income from continuing operations
of $308.2 million and net income per diluted share from continuing operations of $3.45 in Fiscal
2008. Net income per diluted share from continuing operations included non–cash, store–related
asset impairment charges of $0.23 and $0.06 for Fiscal 2009 and Fiscal 2008, respectively. Net cash
provided by operating activities, the Company's primary source of liquidity, was $402.2 million for
Fiscal 2009. This source of cash was primarily driven by results from operations adjusted for non–
cash items including depreciation and amortization and impairment charges. The Company used
$175.5 million of cash for capital expenditures and had proceeds from the sale of marketable
securities of $77.5 million during Fiscal 2009.
The Company's Market Share may be Adversely Impacted at any Time by a Significant Number of
Competitors. The sale of apparel and personal care products is a highly competitive business with
numerous participants, including individual and chain fashion specialty stores, as well as regional
and national department stores. The Company faces a variety of competitive challenges, including
maintaining favorable brand recognition and effectively marketing its products to consumers in
several diverse demographic markets. And sourcing merchandise

Developing Cell Specific Cancer Treatments
Developing Cell–Specific Cancer Treatments
Introduction: Cancer treatment is extremely costly, frequently physically taxing and never
guaranteed to work. However, as drug companies such as ours strive to improve conditions with
regard to the latter two characteristics, we must face a worsening set of conditions with respect to
the first characteristic. The focus of our discussion is on using newly focused ways of fighting
cancer cells without attacking their healthy host cells, particularly with an emphasis on the genetic
characteristics of breast cancer treatment. We proceed with the thesis that there is great opportunity
for the improvement of treatment outcomes and financial growth potential for our drug company
with the development of a breast–cancer cell–specific drug therapy, but this opportunity will come
with a high price tag to the patient, insurance company and healthcare system.
Economic Issues: There is a genuine, pressing economic concern which enters into this discussion.
Namely, as pharmaceutical companies make apparent strides in the versatility and dynamism of
cancer treatment drugs, the FDA remains behind schedule in approving their mainstream use for full
insurance coverage. The result is that many such treatments remain costly to patients at a rate that
few to no insurance policies will cover in total. According to Goozner (2012), "unaffordable new
drugs, even when they're covered by insurance, are being rationed by price as patients, doctors

Harverd Case Roche
Advanced Corporate Finance
Final Case: Roche
1
2
Reasons for Roche's 100% ownership of Genentech
Since Roche and Genentech both operate in the pharmaceutical industry, but still have their own
specialty, they can benefit from a partnership. Roche owns a majority stake in Genentech since 1990
and since 2007, it owns 56% of Genentech. Genentech was founded in 1976, their focus lies on
biotechnology in which they are the second largest firm of the world.
Genentech had become an important part of Roche's business representing 24% of Roche's
pharmaceutical product sales in 2008. In July 2008, Roche made public that they'd want to acquire
the remaining 44% of Genentech. For Roche this acquisition beholds several benefits, but of ...
Show more content on Helpwriting.net ...
Thus the constraint between Roche's and Genentech's R&D efforts would disappear. Since the
R&D pipeline of Genentech grew stronger by the day in the ten years before the announcement
(see exhibit A, B and C), a merge would be a big advantage to Roche.
Finally, since the beginning of 2007, the free cash flow of Genentech grew largely. Roche could not
access Genentech's cash directly under the present ownership structure. If a merge occurred, Roche
would gain full access to the cash of Genentech. Because expectations are that Genentech's cash
flow will remain high, full access to this cash would have many advantages to Roche, like repaying
the debt made by the acquisition.
Risks
Besides the benefits, there are also several risks involved with the takeover. First, the takeover
would cost $44 billion, which partially would have to be loaned. The management wasn't sure that
Roche would be able to raise the required debt funding given the state of the financial markets. In
the middle of the financial crisis, banks weren't very keen in arranging bridge loans to finance such
acquisitions. As a result of this, even if they were able to manage in getting a bridge loan, this would
be very expensive.
Secondly, it is very hard to value the benefits to Roche in taking over Genentech. One of the causes
of a misvaluation is that synergies tend to be mispriced. On top of that,

23andme Case Summary
In this article Megan Molteni goes into detail about the company 23ANDME and its new business
plan to both increase the company's profit while helping combat genetic disease such as Parkinson.
Recently 23andMe was able to obtain an astonishing $1.75 billion valuation. Which is a very big
accomplishment for a tech company. This company was able to make in its fortune by selling spit
kits priced at $99 that allow the consumer to see their genetic makeup and ancestry. As well as some
information regarding health such as having an increased chance of contracting Parkinson's disease.
In the future 23andMe hopes to give a wider range of information on health risks by identifying the
disease carrying genes. The way to make this possible is by turning

Pharmacy
VentureNavigator
Facebook Login | Sign Up | Login
Home
Assessment
Resources
Community
About
Contact
Resources
Not Rated
A Recent History Of The Pharmaceutical Industry – Based On All Five Forces
August 2007 (The New Business Road Test) ProductionIntellectual
PropertyCompetitionMarketsBusiness ModelPorters 5 Forces.
Similar Articles:
Going Digital: A Sound Guide for Songwriters and Musicians
T–Shirts and Suits: A Guide to the Business of Creativity
Creativebias Helpsheet: Conducting and Using Market Research – Design
Others Also Viewed:
Barriers to Entry
Competitive Rivalry
Investor Groups and Angel Communities in Scotland ... Show more content on Helpwriting.net ...
This highly favourable competitive environment, in which drug companies obtained patents to

protect them from rivals, meant that competitors were effectively blocked from manufacturing and
marketing drugs with the same chemical composition for 17 years, which equates to between eight
and 12 years once the drug actually gets to market.
The result? In terms of threat of entry, the picture of the pharmaceutical industry in the 1980s was
clear. Entry barriers were extremely high, resulting in little threat of entry, a very favourable
condition for industry incumbents and for new pharmaceutical startups that could find a way to
enter.
Supplier power
Pharmaceutical companies were flooded with raw material suppliers anxious to sell to such a strong
and profitable industry. In 1982, there were over 12,000 chemical companies in the USA alone.
Their products had long shelf lives, were readily available from numerous sources, and were bought
largely on the basis of price and delivery. These conditions left the chemical suppliers with little
power to set the terms and conditions under which their raw chemicals were sold to the drug
companies. From the drug companies' point of view, supplier power was virtually nonexistent.
Buyer power
How would you like to be in an industry where your buyers are uninformed about your product and
almost 100 per cent

Genetically Modified Organisms Are Bad Essay

Recommended

Recommended

More Related Content

More from Carla Bennington

More from Carla Bennington (20)

Recently uploaded

Recently uploaded (20)

Genetically Modified Organisms Are Bad Essay